Cargando…
Topiramate-induced acute onset myopia: a case report
BACKGROUND: Topiramate is a drug which emerged from its anticonvulsant properties and now over the years is used for a wider range of indications, including migraine prophylaxis. We described a very rare case of topiramate induced acute onset myopia during use for migraine. It is the first reported...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177415/ https://www.ncbi.nlm.nih.gov/pubmed/25240257 http://dx.doi.org/10.1186/1756-0500-7-665 |
_version_ | 1782336768325976064 |
---|---|
author | Medagama, Arjuna Senaratne, Tissa Bandara, Jayasuriya Mudiyanselage Ruwanthi Panchali Abeysekera, Rajitha Asanga Imbulpitiya, Imbulpitiya Vidanalage Buddhini |
author_facet | Medagama, Arjuna Senaratne, Tissa Bandara, Jayasuriya Mudiyanselage Ruwanthi Panchali Abeysekera, Rajitha Asanga Imbulpitiya, Imbulpitiya Vidanalage Buddhini |
author_sort | Medagama, Arjuna |
collection | PubMed |
description | BACKGROUND: Topiramate is a drug which emerged from its anticonvulsant properties and now over the years is used for a wider range of indications, including migraine prophylaxis. We described a very rare case of topiramate induced acute onset myopia during use for migraine. It is the first reported case of its kind from Sri Lanka with only a handful of reported cases in world literature. CASE PRESENTATION: A 35-year-old Sri Lankan female presented with long standing history of intermittent headache with recent worsening. A diagnosis of migraine was made and due to poor response to other medication was initiated on topiramate. Two weeks later patient developed visual impairment which was finally attributed to topiramate. Following discontinuation of the drug, within 3 days the symptoms started to improve with full recovery in 10 days. CONCLUSION: All clinicians should be aware of the potential ocular side effects of topiramate. Although relatively rare, prompt recognition is key to appropriate management. |
format | Online Article Text |
id | pubmed-4177415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41774152014-09-29 Topiramate-induced acute onset myopia: a case report Medagama, Arjuna Senaratne, Tissa Bandara, Jayasuriya Mudiyanselage Ruwanthi Panchali Abeysekera, Rajitha Asanga Imbulpitiya, Imbulpitiya Vidanalage Buddhini BMC Res Notes Case Report BACKGROUND: Topiramate is a drug which emerged from its anticonvulsant properties and now over the years is used for a wider range of indications, including migraine prophylaxis. We described a very rare case of topiramate induced acute onset myopia during use for migraine. It is the first reported case of its kind from Sri Lanka with only a handful of reported cases in world literature. CASE PRESENTATION: A 35-year-old Sri Lankan female presented with long standing history of intermittent headache with recent worsening. A diagnosis of migraine was made and due to poor response to other medication was initiated on topiramate. Two weeks later patient developed visual impairment which was finally attributed to topiramate. Following discontinuation of the drug, within 3 days the symptoms started to improve with full recovery in 10 days. CONCLUSION: All clinicians should be aware of the potential ocular side effects of topiramate. Although relatively rare, prompt recognition is key to appropriate management. BioMed Central 2014-09-21 /pmc/articles/PMC4177415/ /pubmed/25240257 http://dx.doi.org/10.1186/1756-0500-7-665 Text en © Medagama et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Medagama, Arjuna Senaratne, Tissa Bandara, Jayasuriya Mudiyanselage Ruwanthi Panchali Abeysekera, Rajitha Asanga Imbulpitiya, Imbulpitiya Vidanalage Buddhini Topiramate-induced acute onset myopia: a case report |
title | Topiramate-induced acute onset myopia: a case report |
title_full | Topiramate-induced acute onset myopia: a case report |
title_fullStr | Topiramate-induced acute onset myopia: a case report |
title_full_unstemmed | Topiramate-induced acute onset myopia: a case report |
title_short | Topiramate-induced acute onset myopia: a case report |
title_sort | topiramate-induced acute onset myopia: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177415/ https://www.ncbi.nlm.nih.gov/pubmed/25240257 http://dx.doi.org/10.1186/1756-0500-7-665 |
work_keys_str_mv | AT medagamaarjuna topiramateinducedacuteonsetmyopiaacasereport AT senaratnetissa topiramateinducedacuteonsetmyopiaacasereport AT bandarajayasuriyamudiyanselageruwanthipanchali topiramateinducedacuteonsetmyopiaacasereport AT abeysekerarajithaasanga topiramateinducedacuteonsetmyopiaacasereport AT imbulpitiyaimbulpitiyavidanalagebuddhini topiramateinducedacuteonsetmyopiaacasereport |